Incyte (NASDAQ: INCY) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Incyte to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Incyte and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte 0 4 17 0 2.81
Incyte Competitors 511 2400 6608 122 2.66

Incyte currently has a consensus price target of $145.63, suggesting a potential upside of 47.12%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.76%. Given Incyte’s stronger consensus rating and higher probable upside, equities analysts plainly believe Incyte is more favorable than its rivals.

Risk & Volatility

Incyte has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Incyte’s rivals have a beta of 1.53, indicating that their average stock price is 53% more volatile than the S&P 500.

Profitability

This table compares Incyte and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incyte -10.90% -12.91% -7.41%
Incyte Competitors -3,286.65% -532.93% -41.27%

Earnings and Valuation

This table compares Incyte and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Incyte $1.11 billion $104.22 million -123.74
Incyte Competitors $215.30 million -$39.34 million -74.04

Incyte has higher revenue and earnings than its rivals. Incyte is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

90.9% of Incyte shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 17.7% of Incyte shares are held by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Incyte beats its rivals on 10 of the 12 factors compared.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.